PT 611 - Dylan Beynon - Mindbloom

Psychedelics Today

Psychedelics Today, LLC

Life Sciences, Science, Medicine, Health & Fitness

4.6 • 598 Ratings

🗓️ 1 July 2025

⏱️ 94 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Dylan Beynon: At-Home Ketamine Therapy, Big Pharma Pushback, and the Future of Psychedelic Accessibility

In this episode, Joe Moore welcomes Dylan Beynon, CEO and Founder of Mindbloom, one of the largest providers of legal, at-home ketamine therapy in the U.S.

Dylan shares the deeply personal story that led him to psychedelic medicine—including the tragic loss of his mother and sister to addiction and mental illness—and how these experiences continue to fuel his mission to make psychedelic therapy affordable and accessible for all. Mindbloom has now facilitated over 654,000 sessions across 38 states, offering both sublingual and subcutaneous (injectable) ketamine in a comprehensive treatment program that includes preparation, integration, music, journaling, and even generative AI art.

The conversation dives into common criticisms of at-home ketamine, the benefits of guided treatment over IV infusions, and the disturbing influence of Big Pharma in media narratives—especially the growing PR push behind SPRAVATO. Dylan also breaks down what makes Mindbloom's outcomes stand out, why they recently added injectable ketamine, and how their safety data challenges popular misconceptions.

Joe and Dylan also touch on the potential future of at-home MDMA therapy, regulatory hurdles, and what it will take to scale these powerful treatments to millions of people in need.

If you're in the psychedelic field, considering ketamine therapy, or curious about the ethics and economics of psychedelic medicine, this episode offers a powerful look behind the curtain.

Resources:

Transcript

Click on a timestamp to play from that location

0:00.0	Hello, everybody and welcome back to Psychedelics today. This is Joe Moore. Today on the show,
0:25.3	we have Dylan from Mind Bloom. He's a CEO and founder over there. Today, we get into all sorts of
0:32.0	stuff. We get into at-home ketamine, which I'm a big proponent of. And we kind of dig into some of the criticisms
0:39.6	of at home ketamine. We dig into Spravado plenty and much more. And I want to just say up front,
0:47.4	I really appreciated Dylan coming on the show and digging in with me and, you know, spending time
0:53.7	exploring a lot of things around
0:57.3	ketamine. I, I think ketamine is an essential medicine. I think it's going to be important in the,
1:02.5	in the long term for psychiatry, not just the short term, like thinking mushrooms and everything
1:06.9	coming online or psilocybin and MDMA coming coming online i think it's still going to be really
1:11.6	helpful and useful for a long time and i think yes there's a lot of serious conversations we need
1:19.2	to have about ketamine and let's do it let's have those conversations so if you want and you're
1:24.9	in the ketamine business reach out to us info at psychedelics today.com.
1:29.1	I do want to hear your feedback and I want to have discussions with people who are deep in
1:33.3	the trenches. So please reach out and I do want to engage. So yeah, thanks. Thanks for that.
1:41.0	And yeah, again, thank you, Dylan. Thank you, Mind Bloom, for joining.
1:46.0	Yeah, I'm excited to hear what everybody thinks.
1:48.6	And I'm, you know, I really want to try a course of at-home ketamine treatment,
1:53.0	though I've just not been able to figure it out yet.
1:55.7	So I'll report back when I do.
1:59.8	All right.
2:00.1	So coming up on the psychedelics today schedule, we have navigating psychedelics,
2:05.7	psychedelic essentials for clinicians and wellness professionals.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Psychedelics Today, LLC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Psychedelics Today, LLC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.